Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is an endocrine-gynecology disorder affecting many women of childbearing age. Although a part of the involved mechanism in PCOS occurrence is discovered, the exact etiology and pathophysiology are not comprehensively understood yet. We searched PubMed for PCOS pathogenesis and management in this article and ClinicalTrials.gov for information on repurposed medications. All responsible factors behind PCOS were thoroughly evaluated. Furthermore, the complete information on PCOS commonly prescribed and repurposed medications is summarized through tables. Epigenetics, environmental toxicants, stress, diet as external factors, insulin resistance, hyperandrogenism, inflammation, oxidative stress, and obesity as internal factors were investigated. Lifestyle modifications and complementary and alternative medicines are preferred first-line therapy in many cases. Medications, including 3-hydroxy-3-methyl-3-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, glucose-like peptide-1 receptor agonists, mucolytic agents, and some supplements have supporting data for being repurposed in PCOS. Since there are few completed clinical trials with a low population and mostly without results on PCOS repurposed medications, it would be helpful to do further research and run well-designed clinical trials on this subject. Moreover, understanding more about PCOS would be beneficial to find new medications implying the effect via the novel discovered routes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperandrogenism, hyperinsulinism and insulin resistance (IR) are the main drivers of clinical, metabolic and reproductive phenotypes of PCOS.”
From Low-Calorie Ketogenic Diet: Potential Application in the Treatment of Polycystic Ovary Syndrome in Adolescents (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, the DAI has been developed as a more specific measure of adipose tissue dysfunction by combining WC, BMI, TG levels, and HDL-C [9,10,11].”
From Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The VAI is an established marker of abdominal obesity and IR, integrating WC, triglyceride (TG) levels, and high-density lipoprotein cholesterol (HDL-C) to predict metabolic risk.”
From Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study (2025) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083 · cited 3×
“In addition, it should be mentioned that studies on PCOS women approved the resemblance of their fatty tissue to men, and hence the effect of HA on adipose tissue dysfunction [8].”
BackgroundInfluentialRosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603 · cited 9×
“Hyperinsulinemia increases LH-binding sites and androgen-producing response to LH [44].”
BackgroundInfluentialChronic Low Grade Inflammation in Pathogenesis of PCOS
Rudnicka, E., Suchta, K., Grymowicz, M., Calik-Ksepka, A., Smolarczyk, K., Duszewska, A. M., Smolarczyk, R., & Meczekalski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073789 · Cited by 680
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653
Sanchez-Garrido, M. A., & Tena-Sempere, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.001 · Cited by 557 · cited 1×
“One way androgen results in oxidative stress is by increasing MNC sensitivity to glucose and aggravating glucosestimulated oxidative stress [65].”
BackgroundPolycystic Ovarian Syndrome: Correlation Between Hyperandrogenism, Insulin Resistance and Obesity.
Zeng, X., Xie, Y.-J., Liu, Y.-T., Long, S.-L., & Mo, Z.-C. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.11.003 · Cited by 525 · cited 9×
“It also plays a role in progesterone and estrogen production, ovulation, and decreased GnRH secretion [52].”
BackgroundInfluentialA novel and compact review on the role of oxidative stress in female reproduction
Lu, J., Wang, Z., Cao, J., Chen, Y., & Dong, Y. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0391-5 · Cited by 481 · cited 11×
“Taking SFAs induces inflammation by triggering an increase in TNF-α level in circulation and expressing a specific cytokine suppressor [36].”
BackgroundInfluentialIbáñez, L., Oberfield, S. E., Witchel, S., Auchus, R. J., Chang, R. J., Codner, E., Dabadghao, P., Darendeliler, F., Elbarbary, N. S., Gambineri, A., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479371 · Cited by 463 · cited 7×
“This receptor hypomethylation leads to higher gene expression and sensitivity to LH [18,20].”
BackgroundInfluentialCharacteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442 · cited 3×
“Excess abdominal fat is also responsible for the inflammatory condition [6,44,81].”
BackgroundCassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016) · Human Reproduction · doi:10.1093/humrep/dew243 · Cited by 415 · cited 1×
“On the other hand, hyperinsulinemia reduces hepatic SHBG [18,32,40,49,52,54–56], increasing free testosterone levels in blood [18,32,52,54,56].”
Background
Research works printed but not linked: 3
- Casadesús J. Noyer-Weidner M. Epigenetics Brenner’s Encyclopedia of Genetics 2nd ed. Maloy S. Hughes K. Academic Press San Diego, CA, USA 2013 500 503
- Jones L. Regan F. Endocrine Disrupting Chemicals Encyclopedia of Analytical Science 3rd ed. Worsfold P. Poole C. Townshend A. Miró M. Academic Press Oxford, UK 2019 31 38
- Zeind C.S. Carvalho M.G. Applied Therapeutics: The Clinical Use of Drugs Wolters Kluwer Health Philadelphia, PA, USA 2017
Cited by
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
“These two effects together lead to hyperandrogenaemia and follicular development disorders in PCOS [13].”
BackgroundThe latest reports and treatment methods on polycystic ovary syndrome
Stańczak, N. A., Grywalska, E., & Dudzińska, E. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2357737 · Cited by 193
“Even a slight weight loss of just 5% of initial body weight can lead to improvements in lipid parameters, carbohydrate metabolism and insulin profile [65].”
BackgroundIjaz, S., Iqbal, J., Abbasi, B. A., Ullah, Z., Yaseen, T., Kanwal, S., Mahmood, T., Sydykbayeva, S., Ydyrys, A., Almarhoon, Z. M., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114687 · Cited by 135
RetractedShrivastava, S., & Conigliaro, R. L. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.10.004 · Cited by 116
Advances in the study of the correlation between insulin resistance and infertility
Lei, R., Chen, S., & Li, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1288326 · Cited by 96
Zhan, W., Tang, W., Shen, X., Xu, H., & Zhang, J. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.137463 · Cited by 89
Mohi-ud-din, R., Chawla, A., Sharma, P., Mir, P. A., Pottoo, F. H., Reiner, Ž., Reiner, I., Ateşşahin, D. A., Sharifi‐Rad, J., Mir, R. H., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01275-4 · Cited by 93
“Therefore, a novel concept of the use of old FDA-approved drugs is the recent direction to help clinicians and researchers, and, of course, the patients [24].”
BackgroundQuestioning PCOS phenotypes for reclassification and tailored therapy
Myers, S. H., Russo, M., Dinicola, S., Forte, G., & Unfer, V. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.08.005 · Cited by 74
Update on Management of Cardiovascular Diseases in Women
Lucà, F., Abrignani, M. G., Parrini, I., Fusco, S. A. D., Giubilato, S., Rao, C. M., Piccioni, L., Cipolletta, L., Passaretti, B., Giallauria, F., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051176 · Cited by 69
Liu, M., Guo, S., Li, X., Tian, Y., Yu, Y., Tang, L., Sun, Q., Zhang, T., Fan, M., Zhang, L., et al. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s484531 · Cited by 68
Zhang, J., Xing, C., Cheng, X., & He, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1003238 · Cited by 73
“Based on the advantages of both anthropometric and metabolic profiles, the emergence of SGLT-2 inhibitors for PCOS treatment has aroused general interest (27, 37).”
BackgroundOptimized Machine Learning for the Early Detection of Polycystic Ovary Syndrome in Women
Panjwani, B., Yadav, J., Mohan, V., Agarwal, N., & Agarwal, S. (2025) · Sensors · doi:10.3390/s25041166 · Cited by 77
Polycystic ovary syndrome: Causes, symptoms, pathophysiology, and remedies
Chaudhuri, A. (2023) · Obesity Medicine · doi:10.1016/j.obmed.2023.100480 · Cited by 72
Polycystic ovary syndrome: Current scenario and future insights
Kulkarni, S., Gupta, K. A., Ratre, P., Mishra, P. K., Singh, Y., Biharee, A., & Thareja, S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103821 · Cited by 66
The role of the thyroid in polycystic ovary syndrome
Fan, H., Ren, Q., Sheng, Z., Deng, G., & Li, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1242050 · Cited by 61
Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Livadas, S., Thymis, J., Peppa, Μ., Kalantaridou, S., Oikonomou, E. K., et al. (2024) · Medicina · doi:10.3390/medicina60101656 · Cited by 63
“Environmental factors, mitochondrial dysfunction, is characterized by a reduced ability of these peripheral tissues to respond to normal or elevated concentrations of insulin [39].”
BackgroundMeng, Y., Zhao, T., Zhang, R., Zhu, X., Ma, C., & Shi, Q. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1514250 · Cited by 43
Effects of Ketogenic Diet on Reproductive Hormones in Women With Polycystic Ovary Syndrome
Khalid, K., Apparow, S., Mushaddik, I. L., Anuar, A., Rizvi, S. A. A., & Habib, A. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad112 · Cited by 48
“Apart from the routine prescription of (combined) oral contraceptives, antiandrogen agents, insulin sensitizers, and/ or ovulation inducers, the primary first-line therapy has always been lifestyle interventions that include dietary modification and physical activity to promote weight loss of at least 5% to 10% in wom…”
BackgroundMichele, S. D., Fulghesu, A. M., Pittui, E., Cordella, M., Sicilia, G., Mandurino, G., D’Alterio, M. N., Vitale, S. G., & Angioni, S. L. (2025) · Biomedicines · doi:10.3390/biomedicines13020453 · Cited by 57
“The diagnosis of PCOS requires the careful application of well-established diagnostic criteria, including clinical or biochemical hyperandrogenism, assessment of ovarian morphology, and evaluation of menstrual irregularities [4,5].”
Yang, Y., Zhou, C.-C., Hu, H., Fukuzawa, I., & Zhang, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1035929 · Cited by 39
Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease
Dubey, P., Reddy, S., Sharma, K., Johnson, S., Hardy, G., & Dwivedi, A. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02050-5 · Cited by 51
“These two effects together lead to hyperandrogenemia and follicular development disorders in PCOS [95].”
Impact of Reductive Stress on Human Infertility: Underlying Mechanisms and Perspectives
Moustakli, E., Zikopoulos, A., Skentou, C., Katopodis, P., Domali, E., Potiris, A., Stavros, S., & Zachariou, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111802 · Cited by 39
“This imbalance may occur in the pathogenesis of infertility, pregnancy complications, and other reproductive Additionally, reduced efficacy in antioxidant systems is linked to age-related declines in fertility [72]. disorders.”
BackgroundYang, S., Liu, C., Ma, S., Chang, W.-H., Chen, Y., Lee, W.-L., & Wang, P. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19159094 · Cited by 40
Novakovic, S., Jakovljevic, V. L., Jović, N., Andrić, K., Milinković, M., Anicic, T., Pindović, B., Kareva, E. N., Фисенко, В. П., Dimitrijević, A., et al. (2024) · Antioxidants · doi:10.3390/antiox13040392 · Cited by 45
Effects of intestinal flora on polycystic ovary syndrome
Liu, J., Liu, Y., & Li, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1151723 · Cited by 43
Xu, H., Mao, X., Nie, Z., & Li, Y. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.04.002 · Cited by 37
Glycemic Index and Glycemic Load Estimates in the Dietary Approach of Polycystic Ovary Syndrome
Manta, A., Paschou, S. Α., Isari, G., Mavroeidi, I., Kalantaridou, S., & Peppa, Μ. (2023) · Nutrients · doi:10.3390/nu15153483 · Cited by 38
“The key factor in the development of PCOS, which contributes to increased androgen synthesis and the clinical and biochemical symptoms of the condition, is a malfunction in the ovary, due to both genetic and environmental factors [3,5].”
BackgroundInfluentialTsai, Y.-R., Liao, Y.-N., & Kang, H. (2023) · Cells · doi:10.3390/cells12172189 · Cited by 39
Duval, C., Wyse, B. A., Tsang, B. K., & Librach, C. L. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01480-7 · Cited by 36
“Consequently, these disruptions manifest as anovu-latory cycles, and increased immature follicles, all which contribute to infertility [45].”
BackgroundLiu, K., Wei, H., Nong, W., Peng, H., Li, Y., Lei, X., & Zhang, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.10.312 · Cited by 35
Hadidi, M., Karimabadi, K., Ghanbari, E., Rezakhani, L., & Khazaei, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1269266 · Cited by 40
Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome
Chen, Y., Wang, G., Chen, J., Wang, C., Dong, X., Chang, H., Yuan, S., Zhao, Y., & Mu, L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae002 · Cited by 41
Hong, L., Xiao, S., Diao, L., Lian, R., Chen, C., Zeng, Y., & Liu, S. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05362-5 · Cited by 40
The gut microbiota: emerging biomarkers and potential treatments for infertility-related diseases
Wang, M., Zheng, L., Ma, S., Zhao, D.-H., & Xu, Y. D. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1450310 · Cited by 36
Chen, W., Huang, Q.-Y., Wang, Z., Zhuang, X., Lin, S., & Shi, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.918805 · Cited by 35
The impact of bisphenol A and its analogs on female reproductive health
Trela, E., & Ajduk, A. (2025) · Reproductive Biology · doi:10.1016/j.repbio.2025.101028 · Cited by 31
Circulating Galectin-3 levels in women with polycystic ovary syndrome: A meta-analysis
Bahreiny, S. S., Bastani, M., Aghaei, M., Dabbagh, M. R., & Mahdizade, A. H. (2024) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2023.10.003 · Cited by 30
Calcaterra, V., Cena, H., Sottotetti, F., Hruby, C., Madini, N., Zelaschi, N., & Zuccotti, G. (2023) · Nutrients · doi:10.3390/nu15163582 · Cited by 27
“The pathogenesis of PCOS remains not fully elucidated, and it is thought to be led by both exogenous and endogenous factors, with hyperandrogenism, hyperinsulinism and insulin resistance (IR) being the main drivers of clinical, metabolic and reproductive phenotypes [3].”
BackgroundLi, R., Hu, R. M., Huang, Y., Li, D., Ma, X., & Yang, Y. (2023) · Endocrine · doi:10.1007/s12020-023-03553-x · Cited by 28
“Although PCOS has been studied for hundreds of years, its exact etiology and pathophysiology remain elusive [4].”
Role of the NLRP3 inflammasome in gynecological disease
Zheng, X., Zhao, D., Jin, Y., Liu, Y., & Liu, D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115393 · Cited by 24
miRNA expression in PCOS: unveiling a paradigm shift toward biomarker discovery
Rashid, G., Khan, N. A., Elsori, D. H., Youness, R. A., Hassan, H., Siwan, D., Seth, N., Kamal, M. A., Rizvi, S., Babker, A. M. A., et al. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07379-4 · Cited by 32
Zhao, H., Zhou, D., Liu, C., & Zhang, L. (2023) · International Journal of Women s Health · doi:10.2147/ijwh.s393594 · Cited by 28
“Many clinical and epidemiological data show that about 70% of women with PCOS have IR, and up to 80% are overweight or obese, especially with abdominal obesity.(33) Obesity and IR may exacerbate PCOS-related ovulation disorders by enhancing follicular excess through AMH dysregulation or the HA pathway.”
BackgroundEndocrine factors associated with infertility in women: an updated review
Concepción‐Zavaleta, M. J., Arroyo, J., Aldave, J. E. Q., Durand‐Vásquez, M. D. C., Ildefonso-Najarro, S. P., Rafael-Robles, L. D. P., Urteaga, L. A. C., Osorio, E. R. G., Suárez-Rojas, J., & Paz‐Ibarra, J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256405 · Cited by 34
Waghmare, S. V., & Shanoo, A. (2023) · Cureus · doi:10.7759/cureus.47408 · Cited by 40
Edaravone: A Novel Possible Drug for Cancer Treatment?
Duranti, E., Cordani, N., & Villa, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031633 · Cited by 26
Polycystic Ovary Syndrome and Reproductive Health: A Comprehensive Review
Hussein, R., Dayel, S. B., & Abahussein, O. (2024) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5112269 · Cited by 27
Chen, W., Miao, J., Chen, J., & Chen, J. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-024-01583-1 · Cited by 24
Reactive oxygen and nitrogen species: multifaceted regulators of ovarian activity
Bezdíček, J., Sekaninová, J., Janků, M., Makarevič, A., Luhová, L., Dujíčková, L., & Petřivalský, M. (2025) · Biology of Reproduction · doi:10.1093/biolre/ioaf032 · Cited by 28
“Polycystic ovary syndrome (PCOS) belongs to endocrine disorders of heterogenous origin, highly prevalent in women of reproductive age and associated with dysfunctional ovaries, increased androgens, and insulin resistance [195, 196].”
Mahabamunuge, J., Sekula, N. M., Lepore, C., Kudrimoti, M., Upadhyay, A., Alshowaikh, K., Li, H. J., Seifer, D. B., & AlAshqar, A. (2025) · Biomedicines · doi:10.3390/biomedicines13030709 · Cited by 30
ASPORIN: A root of the matter in tumors and their host environment
Lall, S. P., Alsafwani, Z. W., Batra, S. K., & Seshacharyulu, P. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189029 · Cited by 30
A real‐world disproportionality analysis of semaglutide: Post‐marketing pharmacovigilance data
Du, Y., Zhang, M., Wang, Z., Hu, M., Xie, D., Wang, X., Guo, Z., Zhu, J., Zhang, W., Luo, Z., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14229 · Cited by 25
“In addition, we found an AE – polycystic ovary which ranked 10th among hepatobiliary system PTs. Polycystic ovary syndrome (PCOS) is a highly prevalent condition that represents the most common endocrine metabolic disorder among women of reproductive age 41 .”
BackgroundCui, X., Lei, X., Huang, T., Mao, X., Shen, Z., Yang, X., Peng, W., Yu, J., Zhang, S., & Huo, P. F. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01542-w · Cited by 23
“Polycystic ovary syndrome (PCOS) is an endocrine disorder with a widespread prevalence in women of reproductive age, and it is mainly characterized by excessive androgen secretion, ovulatory dysfunction, and the presence of polycystic ovaries [1, 2].”
Chen, J.-Y., Chen, W.-J., Zhu, Z.-Y., Shi, X., Huang, L.-L., Tan, W.-Q., Zhang, Y., & Zhao, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313494 · Cited by 23
Understanding polycystic ovary syndrome in light of associated key genes
Bhimwal, T., Puneet, & Priyadarshani, A. (2023) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-023-00418-w · Cited by 27
“Unhealthy eating habits, lifestyle choices and infectious agents further contribute to disease severity and progression [9, 10].”
BackgroundThe ZDHHC13/ZDHHC17 subfamily: From biological functions to therapeutic targets of diseases
Zhang, Y., Fan, S., He, L., & Li, L. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107418 · Cited by 23
Zhang, Z., Shi, C., & Wang, Z. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1279469 · Cited by 22
Heidarpour, M., Mojarad, M., Mazaheri‐Tehrani, S., Kachuei, A., Najimi, A., Shafie, D., & Rezvanian, H. (2024) · International Journal of Endocrinology · doi:10.1155/2024/9900213 · Cited by 23
“It is characterized by diferent metabolic and hormonal abnormalities such as oligoovulation or anovulation, hyperandrogenism, insulin resistance (IR), type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, and ultrasound fndings including polycystic ovary [3, 4].”
BackgroundAzam, S. S., Vasudevan, S., Bukhari, W. S., Thadhani, J., Tasneem, H., Singh, S., Chijioke, I., de Freitas, B. M., Thammitage, M. B. W., & Motwani, J. (2025) · Cureus · doi:10.7759/cureus.78222 · Cited by 24
“Sometimes surgical procedures are performed to improve ovarian function and fertility outcomes [8].”
Zanjirband, M., Baharlooie, M., Safaeinejad, Z., & Nasr‐Esfahani, M. H. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106601 · Cited by 21
Zhao, H., Wang, D., Xing, C., Lv, B., Wang, X., & He, B. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106265 · Cited by 19
Huang, X., Luo, X., Huang, S., Chen, X., & Qiu, L. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01284-4 · Cited by 19
“The disease is characterized by hyperandro-genemia, ovulation dysfunction, and polycystic changes in ovaries and includes elevated serum luteinizing hormone, hyperinsulinemia, and insulin resistance (IR) (Sadeghi et al. 2022).”
Fereidouni, F., Kashani, L., Amidi, F., Khodarahmian, M., Zhaeentan, S., Ardehjani, N. A., & Rastegar, T. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01504-0 · Cited by 22
“Currently, there is no one ideal treatment for all women with PCOS, so physicians must treat them symptomatically (Helvaci and Yildiz 2023; Sadeghi et al. 2022).”
InfluentialLiang, X., He, H., Zeng, H., Wei, L., Yang, J., Wen, Y., Fan, S., & Fan, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1172750 · Cited by 20
“Exclusion criteria were (1) repeated publications, (2) proceeding paper, editorial material, meeting abstract, book chapters, letters, early access, correction, reprint, and other types.”
BackgroundInfluentialBaranowska-Bik, A. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0047 · Cited by 21
“As a factor affecting adipose tissue activity, insulin also plays a role in the deregulation of adipokine secretion [6].”
BackgroundInfluentialAl-Thuwaynee, S., & Swadi, A. A. J. (2023) · Journal of Medicine and Life · doi:10.25122/jml-2023-0069 · Cited by 19
Khatun, M., Lundin, K., Naillat, F., Loog, L., Saarela, U., Tuuri, T., Salumets, A., Piltonen, T., & Tapanainen, J. S. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10627-w · Cited by 23
“…has vast multimorbidity [3] and is characterized by irregular menstrual cycles, elevated levels of androgens, insulin resistance (IR), ovarian dysfunction, chronic inflammation, impaired glucose metabolism, dyslipidemia, an increased risk of cardiovascular disease (CVD), and mental distress [4–6].”
BackgroundThe Current and Emerging Role of Statins in the Treatment of PCOS: The Evidence to Date
Kolnikaj, T. S., Herman, R., Janež, A., & Jensterle, M. (2024) · Medicina · doi:10.3390/medicina60020244 · Cited by 23
“In addition, their role in accelerated steroidogenesis by limiting one source of cholesterol and providing several other beneficial mechanisms is widely investigated [16].”
BackgroundCalcaterra, V., Magenes, V. C., Bianchi, A., Rossi, V., Gatti, A., Marin, L., Vandoni, M., & Zuccotti, G. (2024) · Life · doi:10.3390/life14091198 · Cited by 23
“In women and adolescents with polycystic ovary syndrome (PCOS), IR in skeletal muscle exacerbates hyperinsulinemia, which, in turn, stimulates excess androgen production by the ovaries, worsening reproductive symptoms [125,126].”
BackgroundSharami, S. H., Vojoudi, E., Zarei‐Behjani, Z., Hasanzadi, A., Shoarishoar, S. S., Vaez, A., & Barabadi, Z. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e43484 · Cited by 20
The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome
Psilopatis, I., Vrettou, K., Nousiopoulou, E., Palamaris, K., & Theocharis, S. E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082912 · Cited by 20
“External risk factors include epigenetic mechanisms such as gene promoter hyper-/hypomethylations, endocrine-disrupting chemicals, physical and emotional stress, as well as nutrient levels [9].”
BackgroundInfluentialPCOS and vitamin D: a clinical appraisal
Sparić, R., Andjić, M., Vergara, D., Morciano, A., D’Oria, O., Baldini, G. M., Malvası, A., & Tinelli, A. (2023) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-023-07227-x · Cited by 17
Wang, X., Zhang, Y., Peng, J., Zhang, H., Jiang, T., Zhang, Z., Yin, T., Su, X. J., Zhang, T., Shen, L., et al. (2024) · Biological Trace Element Research · doi:10.1007/s12011-024-04236-y · Cited by 21
“Several studies have shown that the development of PCOS is associated with genetic susceptibility, epigenetics, diet, oxidative stress, inflammation, and environmental factors [3].”
Li, Y., Song, H., Xu, J., Wang, Y., Bai, L., Wang, H., & Zhang, J. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112381 · Cited by 16
Akpang, N., Kwiatkowski, J., Zaborowska, Ł., & Ludwin, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094121 · Cited by 17
Parua, S., Purkait, M. P., Bhattacharjee, A., Thangarajan, R., Subramanian, R., Islam, K., Bhattacharya, K., & Syamal, A. K. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100619 · Cited by 27
Dou, P., Zhang, T.-T., Xu, Y., Xue, Q., Zhang, Y., Shang, J., & Yang, X.-L. (2024) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303286777240223074922 · Cited by 15
Li, K., Hu, L., Li, X., Yuan, Z., He, J., Liu, D., Yang, G., & Yuan, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01155-1 · Cited by 15
“PCOS is also a chronic inflammatory mediator disorder [4].”
BackgroundOvarian Torsion in Polycystic Ovary Syndrome: A Potential Threat?
Psilopatis, I., Damaskos, C., Garmpis, N., Vrettou, K., Garmpi, A., Antoniou, E., Chionis, A., Nikolettos, K., Kontzoglou, K., & Dimitroulis, D. (2023) · Biomedicines · doi:10.3390/biomedicines11092503 · Cited by 17
“Biguanides may be supplementarily applied in addition to combined oral contraceptives and lifestyle changes with a view to ameliorating menstrual cycle abnormalities, weight, and metabolic outcomes [8].”
BackgroundKhan, A. Y. R., Abdullah, M. A. K., Gul, R., Bhutta, H. R., Imran, M., Mazhar, S. B., & Tariq, N. (2024) · Cureus · doi:10.7759/cureus.52540 · Cited by 23
“It is a heterogeneous condition that affects approximately one in 10 women in their reproductive age [1].”
BackgroundGudović, A., Bukumirić, Z., Milinčić, M., Pupovac, M., Andjić, M., Ivanović, K., & Spremović-Radjenović, S. (2024) · Biomedicines · doi:10.3390/biomedicines12020349 · Cited by 22
“Insulin receptors have been identified in the theca and granulosa cells of the ovary, clearly indicating that the ovary is a target organ for insulin action [7].”
BackgroundRizk, F. H., Saadany, A. A. E., Elshamy, A. M., Ellatif, R. A. A., El-Guindy, D. M., Helal, D. S., Hamama, M. G., El-Sharnouby, J. A., Ghafar, M. T. A., & Faheem, H. (2024) · The Journal of Physiology · doi:10.1113/jp285793 · Cited by 19
“It is accompanied by metabolic abnormalities such as insulin resistance (IR), hyperinsulinaemia, dyslipidaemia, obesity, chronic inflammation and oxidative stress (He & Li, 2020; Sadeghi et al., 2022).”
Liu, S., Zhao, X., Meng, Q., & Li, B. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293447 · Cited by 14
RetractedGestational Diabetes Mellitus in the Setting of Polycystic Ovarian Syndrome: A Systematic Review
Slouha, E., Alvarez, V. C., Gates, K. M., Ankrah, N. M. N., Clunes, L. A., & Kollias, T. F. (2023) · Cureus · doi:10.7759/cureus.50725 · Cited by 24
“Hormonal contraceptives like oral contraceptives, patches, or vaginal rings are effective against the symptoms of PCOS [4,5].”
BackgroundInfluentialShivyari, F. T., Pakniat, H., Nooshabadi, M. R., Rostami, S., Haghighian, H. K., & Shiri‐Shahsavar, M. R. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01432-1 · Cited by 15
Li, J., Liu, D., Zhao, H., Zhang, P., Cai, F., Li, H., & Chu, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112491 · Cited by 15
Hammoudeh, A. J., Jallad, M., Khader, Y. S., Badaineh, Y., Tabbalat, R. A., Zammar, H., Al-Makhamreh, H. K., Basha, A. S., Alatteili, L., Abuhalimeh, R., et al. (2024) · Global Heart · doi:10.5334/gh.1341 · Cited by 14
Zhu, X., Han, Y., Feng, Y., Shan, Y., Liu, C., Wang, K., Li, X., Han, Y., & Han, Y. (2025) · Scientific Reports · doi:10.1038/s41598-024-81110-w · Cited by 14
Naeem, I., Zehra, A., Rehman, F., Hussain, A., Hussain, N., Hussain, N., WASEEM, M., Alqahtani, R. M., Shamlan, G. H., Ahmed, I. A. M., et al. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01741-z · Cited by 22
“Significant differences in physical activity level and nutrient intake (vitamins and polyunsaturated fatty acids) between the groups and food low in glycemic index and glycemic load can improve PCOS [128].”
Tang, L., Du, K., Luo, K., Wang, L., & Hua, F. (2024) · HORMONES · doi:10.1007/s42000-024-00539-w · Cited by 14
Tong, X., Hu, Z., Zhou, H., Zhang, Y., Zhang, Y., Zhang, S., & Jin, J. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.08.012 · Cited by 13
Moka, M. K., Sriram, D. K., & George, M. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.11.015 · Cited by 19
Mohamed, R. A., Taref, N. N., Osman, N. E., Keshta, N. H. A., Alboghdady, M. A., Marzouk, M. M., Almowafy, A. A., & Fadel, E. A. (2024) · BMC Nursing · doi:10.1186/s12912-024-02015-7 · Cited by 21
“After recommending specific lifestyle changes and providing supplemental advice, the standard course of treatment for this issue involves symptomatic therapy using a variety of medications, including contra-ceptives, oral antidiabetics, or antiandrogens [9].”
BackgroundJiang, D., Cai, X.-F., Fang, H., Li, Y., Zhang, Z., Chen, H., Zheng, Z., Wang, W., & Sun, Y. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.136539 · Cited by 15
Choi, Y.-J., Kang, K., Je, M., Lee, Y., & Kim, Y. (2025) · Nutrients · doi:10.3390/nu17040674 · Cited by 16
“A low-GI diet led to a gradual increase in postprandial glycemia, lowering insulin resistance [74] and the risk of PCOS exacerbation [109].”
Zou, L., Li, W., Xu, D., Zhu, S., & Jiang, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01246-7 · Cited by 14
“…only symptomatic treatment such as lifestyle management, taking combination oral contraceptives to regulate menstrual cycles and ameliorate hyperandrogenism, using insulin sensitizers to alleviate IR, taking clomiphene or letrozole to promote ovulation in the case of anovulatory infertility [5–7].”
BackgroundKeyif, B., & Yavuzcan, A. (2025) · Medicina · doi:10.3390/medicina61030424 · Cited by 11
Cong, P., Shang, B., Zhang, L., Wu, Z., Wang, Y., Li, J., & Zhang, L. (2024) · Journal of Molecular Histology · doi:10.1007/s10735-024-10183-8 · Cited by 11
“Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease characterized by chronic anovulation, hyperandrogenemia, and metabolic abnormalities (Hu et al. 2021; Sadeghi et al. 2022).”
Yang, H., Chen, S., Yin, S., & Ding, Q. (2024) · Journal of Applied Toxicology · doi:10.1002/jat.4697 · Cited by 11
Ach, T., Gorchane, A., Methnani, J., Abdessalem, F. B., Nassim, B. H. S., & Asma, B. A. (2024) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514241296777 · Cited by 16
Wu, D., Zhang, Y., Wu, C., An, B., Wang, X., Ni, J., & Chen, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1578470 · Cited by 12
Metadata
- Authors
- Sadeghi, H. M., Adeli, I., Calina, D., Docea, A. O., Mousavi, T., Daniali, M., Nikfar, S., Tsatsakis, A., & Abdollahi, M.
- Affiliations
- Pharmaceutical Sciences Research Center (IR)
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
- University of Medicine and Pharmacy of Craiova (RO)
- Personalized Medicine Research Center (IR)
- University of Crete (GR)
- Corresponding author
- Abdollahi, Mohammad
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-01-06
- Volume
- 23
- Issue
- 2
- Pages
- 583
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8775814
- OpenAlex
- W4205636865
- Cited by
- 445
- References
- 106
- Citations by year
- 2026: 68 · 2025: 136 · 2024: 133 · 2023: 90 · 2022: 18
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, PCOS pathogenesis, drug repurposing, insulin resistance, hyperandrogenism, oxidative stress, inflammation, obesity, epigenetics, environmental toxins, stress, diet, statins, thiazolidinediones, SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, mucolytic agents, lifestyle modification, complementary and alternative medicine
- MeSH terms
- Female, Humans, Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism, Disease Management, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.